New Smart Cap ‘Timesulin’ Offers Major Advance in Diabetes Compliance

Patients Pending Ltd. today announced the consumer launch of Timesulin, an innovative replacement cap that seamlessly transforms all major insulin pens into a smart pen to show how long it’s been since the last insulin injection. This new release represents a major step forward for the huge population of people using insulin to treat their diabetes - of whom up to a third inadvertently skip doses or otherwise fail to take their medication as prescribed. Timesulin offers the first real improvement for traditional insulin pens since their release more than 25 years ago.

This simple, affordable and easy-to-use solution helps avoid missed or accidental double injections - and the accompanying hyper- or hypoglycemic (high or low blood sugar levels) events that cause people with diabetes daily anxiety and potentially life-threatening scenarios. 

At least one recent study, the 2011 report from pharmaceutical firm Novo Nordisk, shows the extent of the problem with missed injections or overdosing. This report, titled the Global Attitudes of Patients and Physicians in Insulin Therapy (GAPP) survey, showed that patients failed to take their insulin as described on average three times in the last month, with 77% of physicians estimating that in reality the number could be as high as six doses per month.

With the World Health Organisation now estimating the global number of people living with diabetes at 366 million - twice as many as 30 years ago - the market for innovation in diabetes management is wide open. 

That’s why Timesulin has already generated excitement amongst established names in the diabetes field in Europe, including Dr Åke Sjöholm, Chief of the Diabetes Research Unit at Sweden’s Karolinska Institutet in Stockholm. “Due to the habitual nature of insulin administration patients often forget whether or not they had injected their insulin dose,” Dr Sjöholm noted. “We regard this as a major challenge in managing diabetes and welcome the timely arrival of an innovative solution like Timesulin.”

“As someone who developed Type 1 diabetes at age three, Timesulin is the solution I’ve always been searching for,” said Timesulin co-founder and CEO, John Sjölund. “A person who doesn’t live with diabetes will wonder how it’s possible to forget when or whether you’ve given yourself an injection, but given the hectic lives we all lead, keeping track of the four-times-a-day ritual can be difficult for anyone living with a chronic condition. It’s like trying to remember if you turned the stove off. We all worry about it sometimes, but when there’s medication involved, it causes real anxiety. That’s why Timesulin offers the perfect solution for people living with diabetes - as well as those near and dear to them.”

The brand’s trade launch in September 2011 at FEND’s annual conference in Lisbon, Portugal, generated considerable enthusiasm in the diabetes treatment community. “In my experience as a nurse consultant in diabetes, the problem of forgetting whether or not the very important insulin injection has been administered is a prominent one,” said Grace Vanterpool, a London-based diabetes nurse consultant and MBE at the Hammersmith and Fulham PCT and Imperial Health Care Trust. “What I like best about Timesulin is that it addresses this huge problem head-on with an easy-to-use solution that requires no programming or change in habit."

The simplicity offered by Timesulin is also cited by another advocate: Helena Farrell, diabetes nurse and founder of the Diabetes Insight Center in Cork, Ireland. “Any modernisation or product that is simple to use and offers people with diabetes a better quality of life is welcome,” Farrell noted. “This is a product that’s badly needed by a great number of people, including many that I treat, and I commend the Timesulin team for bringing it to market.”


Timesulin carries the CE mark, works with all major insulin pens, requires no change in habit and works straight out of the package without any programming required. For additional information, or to purchase Timesulin caps, please visit www.timesulin.com.

Notes for Editors

•  Hi-res images available.

•  Case studies of trial patients who have used Timesulin available.

•  We will facilitate interviews with diabetes specialists familiar with Timesulin, available for interviews.